Burlingame, CA, United States of America

Sundaramoorthi Swaminathan

USPTO Granted Patents = 29 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 10.0

ph-index = 14

Forward Citations = 874(Granted Patents)

Company Filing History:

24 out of 919

Gilead Sciences, Inc.

Isis Pharmaceuticals, Inc.

patents

Years Active: 1998-2025

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

2. 12258346 - Substituted 6-azabenzimidazole compounds (2025-03-25),

3. 11897878 - Substituted 6-azabenzimidazole compounds (2024-02-13),

4. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

5. 11203591 - Substituted 6-azabenzimidazole compounds (2021-12-21),

6. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

7. 10342794 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2019-07-09),

8. 9968601 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2018-05-15),

9. 9931338 - Syk inhibitors (2018-04-03),

10. 9504684 - Syk inhibitors (2016-11-29),

11. 9290505 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2016-03-22),

12. 9139604 - Antiviral phosphonate analogs (2015-09-22),

13. 8022083 - Antiviral phosphonate analogs (2011-09-20),

14. 7842672 - Phosphonate inhibitors of HCV (2010-11-30),

15. 7741345 - AZA-peptide protease inhibitors (2010-06-22),

Certainly! Here is the article about inventor Sundaramoorthi Swaminathan based on the provided data:

Title: Innovator Spotlight: Sundaramoorthi Swaminathan

Introduction:

Sundaramoorthi Swaminathan, a prolific inventor based in Burlingame, CA, has made significant contributions to the field of pharmaceuticals with a remarkable total of 27 patents to his name. His innovative work has brought forth novel compounds and treatments with the potential to combat various diseases and conditions.

Latest Patents:

1. Substituted 6-azabenzimidazole compounds: In his latest patent, Swaminathan introduces 6-azabenzimidazole compounds designed to inhibit hematopoietic progenitor kinase 1 (HPK1), thereby offering promise in the treatment or prevention of diseases such as HBV, HIV, cancer, and hyper-proliferative diseases.

2. Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine: Another innovative patent by Swaminathan includes Syk inhibitors and their pharmaceutical compositions, showing potential in treating cancer and inflammatory conditions.

Career Highlights:

Swaminathan's expertise has been honed through impactful tenures at renowned companies like Gilead Sciences, Inc. and the creatively named Isis Pharmaceuticals, Inc. His rich experience in the pharmaceutical industry has undoubtedly shaped his approach to innovation and patenting groundbreaking technologies.

Collaborations:

Throughout his career, Swaminathan has had the privilege of working alongside esteemed colleagues such as James Ming Chen and Richard L Mackman. These collaborations have not only enriched his professional journey but have also led to the development of cutting-edge solutions in the field of pharmaceuticals.

Conclusion:

In conclusion, Sundaramoorthi Swaminathan's remarkable portfolio of patents underscores his dedication to advancing the realm of pharmaceuticals. His groundbreaking work continues to pave the way for innovative treatments and solutions that hold immense potential in addressing critical healthcare challenges.

If you need more information or have any other requests, feel free to ask!

This text is generated by artificial intelligence and may not be accurate.